{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:31:21Z","timestamp":1794897081783,"version":"4.9.1"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41584-023-01044-x","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T08:02:55Z","timestamp":1698998575000},"page":"21-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Systemic sclerosis interstitial lung disease: unmet needs and potential solutions"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-9334","authenticated-orcid":false,"given":"Vasiliki","family":"Liakouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann, E. R., Andr\u00e9asson, K. & Smith, V. Systemic sclerosis. Lancet 401, 304\u2013318 (2023).","journal-title":"Lancet"},{"key":"1044_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41584-018-0062-0","volume":"14","author":"CP Denton","year":"2018","unstructured":"Denton, C. P., Wells, A. U. & Coghlan, J. G. Major lung complications of systemic sclerosis. Nat. Rev. Rheumatol. 14, 511\u2013527 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1044_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai, M. et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 76, 1897\u20131905 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas, A., Silver, R. M., Arrossi, A. V. & Highland, K. B. Systemic sclerosis-associated interstitial lung disease. Lancet Respir. Med. 8, 304\u2013320 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1044_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00296-016-3636-7","volume":"37","author":"R Giacomelli","year":"2017","unstructured":"Giacomelli, R. et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol. Int. 37, 853\u2013863 (2017).","journal-title":"Rheumatol. Int."},{"key":"1044_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","volume":"400","author":"M Wijsenbeek","year":"2022","unstructured":"Wijsenbeek, M., Suzuki, A. & Maher, T. M. Interstitial lung diseases. Lancet 400, 769\u2013786 (2022).","journal-title":"Lancet"},{"key":"1044_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.autrev.2016.03.005","volume":"15","author":"O Cabral-Marques","year":"2016","unstructured":"Cabral-Marques, O. & Riemekasten, G. Vascular hypothesis revisited: role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. Autoimmun. Rev. 15, 690\u2013694 (2016).","journal-title":"Autoimmun. Rev."},{"key":"1044_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cei.13599","volume":"205","author":"P Di Benedetto","year":"2021","unstructured":"Di Benedetto, P. et al. Endothelial-to-mesenchymal transition in systemic sclerosis. Clin. Exp. Immunol. 205, 12\u201327 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"1044_CR9","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/art.30317","volume":"63","author":"Z Li","year":"2011","unstructured":"Li, Z. & Jimenez, S. A. Protein kinase C\u03b4 and c-Abl kinase are required for transforming growth factor \u03b2 induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum. 63, 2473\u20132483 (2011).","journal-title":"Arthritis Rheum."},{"key":"1044_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161988","volume":"11","author":"PJ Wermuth","year":"2016","unstructured":"Wermuth, P. J., Li, Z., Mendoza, F. A. & Jimenez, S. A. Stimulation of transforming growth factor-\u03b21-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): a novel profibrotic effect of ET-1. PLoS One 11, e0161988 (2016).","journal-title":"PLoS One"},{"key":"1044_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.semarthrit.2010.10.002","volume":"41","author":"A Ludwicka\u2010Bradley","year":"2011","unstructured":"Ludwicka\u2010Bradley, A., Silver, R. M. & Bogatkevich, G. S. Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin. Arthritis Rheum. 41, 212\u2013222 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"1044_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11926-017-0630-3","volume":"19","author":"C Dowson","year":"2017","unstructured":"Dowson, C., Simpson, N., Duffy, L. & O\u2019Reilly, S. Innate immunity in systemic sclerosis. Curr. Rheumatol. Rep. 19, 2 (2017).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1044_CR13","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/art.41418","volume":"72","author":"C Ryu","year":"2020","unstructured":"Ryu, C. et al. Bioactive plasma mitochondrial DNA is associated with disease progression in scleroderma-associated interstitial lung disease. Arthritis Rheumatol. 72, 1905\u20131915 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR14","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1164\/rccm.201712-2410OC","volume":"199","author":"PA Reyfman","year":"2019","unstructured":"Reyfman, P. A. et al. Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 199, 1517\u20131536 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1044_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(21)01961-9","volume":"398","author":"EA Renzoni","year":"2021","unstructured":"Renzoni, E. A., Poletti, V. & Mackintosh, J. A. Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia? Lancet 398, 1437\u20131449 (2021).","journal-title":"Lancet"},{"key":"1044_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clim.2010.06.017","volume":"137","author":"DV Pechkovsky","year":"2010","unstructured":"Pechkovsky, D. V. et al. Alternatively activated alveolar macrophages in pulmonary fibrosis \u2014 mediator production and intracellular signal transduction. Clin. Immunol. 137, 89\u2013101 (2010).","journal-title":"Clin. Immunol."},{"key":"1044_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12931-018-0891-z","volume":"19","author":"AC Trombetta","year":"2018","unstructured":"Trombetta, A. C. et al. A circulating cell population showing both M1 and M2 monocyte\/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir. Res. 19, 186 (2018).","journal-title":"Respir. Res."},{"key":"1044_CR18","doi-asserted-by":"publisher","first-page":"595811","DOI":"10.3389\/fimmu.2021.595811","volume":"12","author":"E Valenzi","year":"2021","unstructured":"Valenzi, E. et al. Disparate interferon signaling and shared aberrant basaloid cells in single-cell profiling of idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. Front. Immunol. 12, 595811 (2021).","journal-title":"Front. Immunol."},{"key":"1044_CR19","doi-asserted-by":"publisher","first-page":"936182","DOI":"10.3389\/fmed.2022.936182","volume":"9","author":"SC Liossis","year":"2022","unstructured":"Liossis, S. C. & Staveri, C. The role of B cells in scleroderma lung disease pathogenesis. Front. Med. 9, 936182 (2022).","journal-title":"Front. Med."},{"key":"1044_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-016-1213-9","volume":"19","author":"O Aravena","year":"2017","unstructured":"Aravena, O. et al. TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients. Arthritis Res. Ther. 19, 8 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"1044_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cei.13477","volume":"201","author":"K Higashioka","year":"2020","unstructured":"Higashioka, K. et al. Generation of a novel CD30+ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis. Clin. Exp. Immunol. 201, 233\u2013243 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"1044_CR22","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar4352","volume":"15","author":"A Fran\u00e7ois","year":"2013","unstructured":"Fran\u00e7ois, A. et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res. Ther. 15, R168 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1044_CR23","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/art.40016","volume":"69","author":"N Dumoitier","year":"2017","unstructured":"Dumoitier, N. et al. Scleroderma peripheral B lymphocytes secrete Interleukin-6 and transforming growth factor \u03b2 and activate fibroblasts. Arthritis Rheumatol. 69, 1078\u20131089 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-016-0993-2","volume":"18","author":"A Fava","year":"2016","unstructured":"Fava, A. et al. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res. Ther. 18, 99 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"1044_CR25","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/art.11080","volume":"48","author":"IG Luzina","year":"2003","unstructured":"Luzina, I. G. et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum. 48, 2262\u20132274 (2003).","journal-title":"Arthritis Rheum."},{"key":"1044_CR26","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.5152\/eurjrheum.2020.19112","volume":"7","author":"A Ramahi","year":"2020","unstructured":"Ramahi, A., Altorok, N. & Kahaleh, B. Epigenetics and systemic sclerosis: an answer to disease onset and evolution? Eur. J. Rheumatol. 7, S147\u2013S156 (2020).","journal-title":"Eur. J. Rheumatol."},{"key":"1044_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/BOR.0000000000000735","volume":"32","author":"C Orvain","year":"2020","unstructured":"Orvain, C., Assassi, S., Avouac, J. & Allanore, Y. Systemic sclerosis pathogenesis: contribution of recent advances in genetics. Curr. Opin. Rheumatol. 32, 505\u2013514 (2020).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1044_CR28","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/art.11173","volume":"48","author":"C Feghali-Bostwick","year":"2003","unstructured":"Feghali-Bostwick, C., Medsger, T. A. Jr & Wright, T. M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 48, 1956\u20131963 (2003).","journal-title":"Arthritis Rheum."},{"key":"1044_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0652-y","volume":"11","author":"PS Ramos","year":"2019","unstructured":"Ramos, P. S. et al. Integrative analysis of DNA methylation in discordant twins unveils distinct architectures of systemic sclerosis subsets. Clin. Epigenetics. 11, 58 (2019).","journal-title":"Clin. Epigenetics."},{"key":"1044_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10067-016-3533-1","volume":"36","author":"M Rubio-Rivas","year":"2017","unstructured":"Rubio-Rivas, M., Moreno, R. & Corbella, X. Occupational and environmental scleroderma. Systematic review and meta-analysis. Clin. Rheumatol. 36, 569\u2013582 (2017).","journal-title":"Clin. Rheumatol."},{"key":"1044_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12931-020-01414-z","volume":"21","author":"M Boesch","year":"2020","unstructured":"Boesch, M. et al. Transcriptomic profiling reveals disease-specific characteristics of epithelial cells in idiopathic pulmonary fibrosis. Respir. Res. 21, 165 (2020).","journal-title":"Respir. Res."},{"key":"1044_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/BOR.0000000000000660","volume":"31","author":"DJ DeMizio","year":"2019","unstructured":"DeMizio, D. J. & Bernstein, E. J. Detection and classification of systemic sclerosis-related interstitial lung disease: a review. Curr. Opin. Rheumatol. 31, 553\u2013560 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1044_CR33","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 65, 2737\u20132747 (2013).","journal-title":"Arthritis Rheum."},{"key":"1044_CR34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","volume":"200","author":"AM Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold, A. M. et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am. J. Respir. Crit. Care Med. 200, 1258\u20131266 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1044_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-020-01459-0","volume":"21","author":"AM Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold, A. M. et al. The need for a holistic approach for SSc-ILD \u2014 achievements and ambiguity in a devastating disease. Respir. Res. 21, 197 (2020).","journal-title":"Respir. Res."},{"key":"1044_CR36","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/art.41415","volume":"72","author":"EJ Bernstein","year":"2020","unstructured":"Bernstein, E. J. et al. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 72, 1892\u20131896 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR37","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1136\/annrheumdis-2014-205637","volume":"73","author":"T Frauenfelder","year":"2014","unstructured":"Frauenfelder, T. et al. Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. Ann. Rheum. Dis. 73, 2069\u20132073 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 76, 1327\u20131339 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR39","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"AM Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold, A. M. et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2, e71\u2013e83 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1044_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","volume":"24","author":"FF Rahaghi","year":"2023","unstructured":"Rahaghi, F. F. et al. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir. Res. 24, 6 (2023).","journal-title":"Respir. Res."},{"key":"1044_CR41","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/acr2.11434","volume":"4","author":"EJ Bernstein","year":"2022","unstructured":"Bernstein, E. J. et al. Computed tomography of the chest to screen for interstitial lung disease in patients with systemic sclerosis at expert scleroderma centers in the United States. ACR Open Rheumatol. 4, 596\u2013602 (2022).","journal-title":"ACR Open Rheumatol."},{"key":"1044_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","volume":"31","author":"D Roofeh","year":"2019","unstructured":"Roofeh, D., Jaafar, S., Vummidi, D. & Khanna, D. Management of systemic sclerosis associated interstitial lung disease. Curr. Opin. Rheumatol. 31, 241\u2013249 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1044_CR43","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3899\/jrheum.141182","volume":"42","author":"D Khanna","year":"2015","unstructured":"Khanna, D. et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD): report from OMERACT CTD-ILD working group. J. Rheumatol. 42, 2168\u20132171 (2015).","journal-title":"J. Rheumatol."},{"key":"1044_CR44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/art.40441","volume":"70","author":"EJ Bernstein","year":"2018","unstructured":"Bernstein, E. J., Khanna, D. & Lederer, D. J. Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists. Arthritis Rheumatol. 70, 971\u2013972 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR45","first-page":"1526","volume":"74","author":"C Bruni","year":"2022","unstructured":"Bruni, C. et al. Developing a screening tool for the detection of interstitial lung disease in systemic sclerosis: the ILD-RISC risk score. Arthritis Rheumatol. 74, 1526 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR46","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3899\/jrheum.180940","volume":"47","author":"M Gutierrez","year":"2019","unstructured":"Gutierrez, M. et al. Ultrasound in the assessment of interstitial lung disease in systemic sclerosis: a systematic literature review by the OMERACT Ultrasound Group. J. Rheumatol. 47, 991\u20131000 (2019).","journal-title":"J. Rheumatol."},{"key":"1044_CR47","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/RHU.0000000000000860","volume":"25","author":"RI Hassan","year":"2019","unstructured":"Hassan, R. I. et al. Lung ultrasound as a screening method for interstitial lung disease in patients with systemic sclerosis. J. Clin. Rheumatol. 25, 304\u2013307 (2019).","journal-title":"J. Clin. Rheumatol."},{"key":"1044_CR48","doi-asserted-by":"publisher","first-page":"SI56","DOI":"10.1093\/rheumatology\/keab801","volume":"61","author":"L Gargani","year":"2022","unstructured":"Gargani, L. et al. Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. Rheumatology 61, SI56\u2013SI64 (2022).","journal-title":"Rheumatology"},{"key":"1044_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11739-015-1329-y","volume":"11","author":"A Gigante","year":"2016","unstructured":"Gigante, A. et al. Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease. Intern. Emerg. Med. 11, 213\u2013217 (2016).","journal-title":"Intern. Emerg. Med."},{"key":"1044_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/1744666X.2023.2198212","volume":"19","author":"A Makol","year":"2023","unstructured":"Makol, A. et al. Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease. Expert Rev. Clin. Immunol. 19, 613\u2013626 (2023).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"1044_CR51","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/diagnostics13081429","volume":"13","author":"M Radi\u0107","year":"2023","unstructured":"Radi\u0107, M. et al. Pulmonary ultrasonography in systemic sclerosis-induced interstitial lung disease \u2014 a systematic review and meta-analysis. Diagnostics 13, 1429 (2023).","journal-title":"Diagnostics"},{"key":"1044_CR52","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1097\/RHU.0000000000001947","volume":"29","author":"M Gomes Guerra","year":"2023","unstructured":"Gomes Guerra, M. et al. The role of lung ultrasound in systemic sclerosis: a systematic review. J. Clin. Rheumatol. 29, e32\u2013e39 (2023).","journal-title":"J. Clin. Rheumatol."},{"key":"1044_CR53","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/annrheumdis-2011-201072","volume":"72","author":"T Barskova","year":"2013","unstructured":"Barskova, T. et al. Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Ann. Rheum. Dis. 72, 390\u2013395 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR54","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.chest.2020.03.075","volume":"158","author":"L Gargani","year":"2020","unstructured":"Gargani, L. et al. Prognostic value of lung ultrasound B-lines in systemic sclerosis. Chest 158, 1515\u20131525 (2020).","journal-title":"Chest"},{"key":"1044_CR55","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s10067-020-05491-9","volume":"40","author":"L Gargani","year":"2021","unstructured":"Gargani, L. et al. Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. Clin. Rheumatol. 40, 1903\u20131912 (2021).","journal-title":"Clin. Rheumatol."},{"key":"1044_CR56","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh, N. S. L. et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248\u20131254 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1044_CR57","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10067-020-04938-3","volume":"39","author":"AM Ferrazza","year":"2020","unstructured":"Ferrazza, A. M. et al. Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER. Clin. Rheumatol. 39, 1537\u20131542 (2020).","journal-title":"Clin. Rheumatol."},{"key":"1044_CR58","doi-asserted-by":"publisher","first-page":"577739","DOI":"10.3389\/fmed.2020.577739","volume":"7","author":"ARS Carvalho","year":"2020","unstructured":"Carvalho, A. R. S. et al. Automatic quantification of interstitial lung disease from chest computed tomography in systemic sclerosis. Front. Med. 7, 577739 (2020).","journal-title":"Front. Med."},{"key":"1044_CR59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/2397198320985377","volume":"6","author":"J Clukers","year":"2021","unstructured":"Clukers, J. et al. Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: an observational study. J. Scleroderma Relat. Disord. 6, 154\u2013164 (2021).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"1044_CR60","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518\u20132528 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1044_CR61","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/rheumatology\/keac535","volume":"62","author":"CP Denton","year":"2023","unstructured":"Denton, C. P. et al. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology 62, 1870\u20131876 (2023).","journal-title":"Rheumatology"},{"key":"1044_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold, A. M. et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann. Rheum. Dis. 80, 219\u2013227 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR63","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 205, e18\u2013e47 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1044_CR64","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1378\/chest.13-2626","volume":"146","author":"TA Winstone","year":"2014","unstructured":"Winstone, T. A. et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146, 422\u2013436 (2014).","journal-title":"Chest"},{"key":"1044_CR65","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3125","volume":"12","author":"S Assassi","year":"2010","unstructured":"Assassi, S. et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res. Ther. 12, R166 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"1044_CR66","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/art.22099","volume":"55","author":"SC Plastiras","year":"2006","unstructured":"Plastiras, S. C. et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 55, 598\u2013602 (2006).","journal-title":"Arthritis Rheum."},{"key":"1044_CR67","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/acr.25070","volume":"75","author":"ER Volkmann","year":"2023","unstructured":"Volkmann, E. R. et al. Association of symptoms of gastroesophageal reflux, esophageal dilation, and progression of systemic sclerosis-related interstitial lung disease. Arthritis Care Res. 75, 1690\u20131697 (2023).","journal-title":"Arthritis Care Res."},{"key":"1044_CR68","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/rheumatology\/kev016","volume":"54","author":"A Man","year":"2015","unstructured":"Man, A. et al. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology 54, 1464\u20131471 (2015).","journal-title":"Rheumatology"},{"key":"1044_CR69","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1093\/rheumatology\/keac091","volume":"61","author":"ER Volkmann","year":"2022","unstructured":"Volkmann, E. R. et al. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Rheumatology 61, 4397\u20134408 (2022).","journal-title":"Rheumatology"},{"key":"1044_CR70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/art.41933","volume":"74","author":"D Khanna","year":"2022","unstructured":"Khanna, D. et al. Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice. Arthritis Rheumatol. 74, 13\u201327 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR71","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/rheumatology\/kez407","volume":"59","author":"S Hoa","year":"2020","unstructured":"Hoa, S., Bernatsky, S., Steele, R. J., Baron, M. & Hudson, M. Canadian Scleroderma Research Group. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. Rheumatology 59, 1108\u20131117 (2020).","journal-title":"Rheumatology"},{"key":"1044_CR72","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.chest.2021.06.014","volume":"160","author":"S Hoa","year":"2021","unstructured":"Hoa, S. et al. Association between immunosuppressive therapy and incident risk of interstitial lung disease in systemic sclerosis. Chest 160, 2158\u20132162 (2021).","journal-title":"Chest"},{"key":"1044_CR73","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1093\/rheumatology\/keab929","volume":"61","author":"S Hoa","year":"2022","unstructured":"Hoa, S., Baron, M. & Hudson, M. Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. Rheumatology 61, 3401\u20133407 (2022).","journal-title":"Rheumatology"},{"key":"1044_CR74","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/art.41668","volume":"73","author":"D Roofeh","year":"2021","unstructured":"Roofeh, D. et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 73, 1301\u20131310 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR75","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3899\/jrheum.180042","volume":"46","author":"H Al-Sheikh","year":"2019","unstructured":"Al-Sheikh, H., Ahmad, Z. & Johnson, S. R. Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality. J. Rheumatol. 46, 1103\u20131108 (2019).","journal-title":"J. Rheumatol."},{"key":"1044_CR76","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/rheumatology\/keac576","volume":"62","author":"A Lescoat","year":"2023","unstructured":"Lescoat, A. et al. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Rheumatology 62, 2178\u20132188 (2023).","journal-title":"Rheumatology"},{"key":"1044_CR77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.autrev.2018.08.003","volume":"18","author":"R Giacomelli","year":"2019","unstructured":"Giacomelli, R. et al. Guidelines for biomarkers in autoimmune rheumatic diseases \u2014 evidence based analysis. Autoimmun. Rev. 18, 93\u2013106 (2019).","journal-title":"Autoimmun. Rev."},{"key":"1044_CR78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s40674-022-00196-3","volume":"8","author":"A Cole","year":"2022","unstructured":"Cole, A. & Denton, C. P. Biomarkers in systemic sclerosis associated interstitial lung disease (SSc-ILD). Curr. Treat. Options Rheum. 8, 152\u2013170 (2022).","journal-title":"Curr. Treat. Options Rheum."},{"key":"1044_CR79","doi-asserted-by":"publisher","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","volume":"55","author":"O Distler","year":"2020","unstructured":"Distler, O. et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur. Respir. J. 55, 1902026 (2020).","journal-title":"Eur. Respir. J."},{"key":"1044_CR80","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/art.41153","volume":"72","author":"SI Nihtyanova","year":"2020","unstructured":"Nihtyanova, S. I. et al. Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol. 72, 465\u2013476 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","volume":"50","author":"N Ishikawa","year":"2012","unstructured":"Ishikawa, N., Hattori, N., Yokoyama, A. & Kohno, N. Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases. Respir. Investig. 50, 3\u201313 (2012).","journal-title":"Respir. Investig."},{"key":"1044_CR82","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655\u20132666 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1044_CR83","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS 2): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708\u2013719 (2016).","journal-title":"Lancet Respir. Med."},{"key":"1044_CR84","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","volume":"15","author":"JG Goldin","year":"2018","unstructured":"Goldin, J. G. et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann. Am. Thorac. Soc. 15, 1286\u20131295 (2018).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"1044_CR85","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/acr2.11125","volume":"2","author":"ER Volkmann","year":"2020","unstructured":"Volkmann, E. R. et al. Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II. ACR Open Rheumatol. 2, 362\u2013370 (2020).","journal-title":"ACR Open Rheumatol."},{"key":"1044_CR86","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962\u20133970 (2006).","journal-title":"Arthritis Rheum."},{"key":"1044_CR87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann. Rheum. Dis. 77, 212\u2013220 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR88","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher, T. M. et al. RECITAL Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir. Med. 11, 45\u201354 (2023).","journal-title":"Lancet Respir. Med."},{"key":"1044_CR89","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s10067-020-05542-1","volume":"40","author":"S Borrirukwisitsak","year":"2021","unstructured":"Borrirukwisitsak, S., Tantayakom, P. & Katchamart, W. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. Clin. Rheumatol. 40, 2779\u20132789 (2021).","journal-title":"Clin. Rheumatol."},{"key":"1044_CR90","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","volume":"40","author":"N Acharya","year":"2020","unstructured":"Acharya, N. et al. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease\u2014 a randomised controlled trial. Rheumatol. Int. 40, 703\u2013710 (2020).","journal-title":"Rheumatol. Int."},{"key":"1044_CR91","first-page":"1045","volume":"74","author":"D Khanna","year":"2022","unstructured":"Khanna, D. et al. Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III [abstract]. Arthritis Rheumatol. 74, 1045\u20131047 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR92","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378, 498\u2013506 (2011).","journal-title":"Lancet"},{"key":"1044_CR93","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490\u20132498 (2014).","journal-title":"JAMA"},{"key":"1044_CR94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35\u201347 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1044_CR95","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","volume":"13","author":"MM Crespo","year":"2016","unstructured":"Crespo, M. M. et al. Lung transplantation in patients with scleroderma compared with pulmonary fibrosis: short and long-term outcomes in a single institution. Ann. Am. Thorac. Soc. 13, 784\u2013792 (2016).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"1044_CR96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/2397198319889549","volume":"5","author":"ER Volkmann","year":"2020","unstructured":"Volkmann, E. R. Natural history of systemic sclerosis-related interstitial lung disease: how to identify a progressive fibrosing phenotype. J. Scleroderma Relat. Disord. 5, 31\u201340 (2020).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"1044_CR97","doi-asserted-by":"publisher","first-page":"1759720X2211164","DOI":"10.1177\/1759720X221116408","volume":"14","author":"C Campochiaro","year":"2022","unstructured":"Campochiaro, C. et al. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Ther. Adv. Musculoskelet. Dis. 14, 1759720X221116408 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1044_CR98","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/ard-2022-222564","volume":"81","author":"Y Allanore","year":"2022","unstructured":"Allanore, Y. et al. SENSCIS-ON trial investigators. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann. Rheum. Dis. 81, 1722\u20131729 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR99","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13075-016-1203-y","volume":"18","author":"ER Volkmann","year":"2016","unstructured":"Volkmann, E. R. et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res. Ther. 18, 305 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"1044_CR100","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/art.41627","volume":"73","author":"S Assassi","year":"2021","unstructured":"Assassi, S. et al. Predictive significance of serum interferon-inducible protein score for response to treatment in systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol. 73, 1005\u20131013 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR101","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2021-221313","volume":"81","author":"S Assassi","year":"2022","unstructured":"Assassi, S. et al. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease. Ann. Rheum. Dis. 81, 854\u2013860 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR102","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","volume":"78","author":"W Wu","year":"2019","unstructured":"Wu, W. et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann. Rheum. Dis. 78, 648\u2013656 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR103","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George, P. M. et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 8, 925\u2013934 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1044_CR104","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.40130","volume":"69","author":"NS Goh","year":"2017","unstructured":"Goh, N. S. et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 69, 1670\u20131678 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR105","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3390\/biomedicines10092129","volume":"10","author":"T Nagy","year":"2022","unstructured":"Nagy, T. et al. Clinical predictors of lung-function decline in systemic-sclerosis-associated interstitial lung disease patients with normal spirometry. Biomedicines 10, 2129 (2022).","journal-title":"Biomedicines"},{"key":"1044_CR106","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/acr2.11398","volume":"4","author":"B Jandali","year":"2022","unstructured":"Jandali, B. et al. The effect of anti-Scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis. ACR Open Rheumatol. 4, 345\u2013351 (2022).","journal-title":"ACR Open Rheumatol."},{"key":"1044_CR107","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3125","volume":"12","author":"S Assassi","year":"2010","unstructured":"Assassi, S. et al. GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res. Ther. 12, R166 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"1044_CR108","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","volume":"77","author":"W Wu","year":"2018","unstructured":"Wu, W. et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann. Rheum. Dis. 77, 1326\u20131332 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR109","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1183\/13993003.01534-2020","volume":"56","author":"F Bonella","year":"2020","unstructured":"Bonella, F. et al. The Gender-Age-Physiology (GAP) index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD). Eur. Resp. J. 56, 801 (2020).","journal-title":"Eur. Resp. J."},{"key":"1044_CR110","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13075-021-02460-8","volume":"23","author":"E Ledoult","year":"2021","unstructured":"Ledoult, E. et al. 18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res. Ther. 23, 76 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1044_CR111","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/rheumatology\/kez483","volume":"59","author":"DM Peelen","year":"2020","unstructured":"Peelen, D. M. et al. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology 59, 1407\u20131415 (2020).","journal-title":"Rheumatology"},{"key":"1044_CR112","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.chest.2022.09.044","volume":"163","author":"AM Hoffmann-Vold","year":"2023","unstructured":"Hoffmann-Vold, A. M. et al. EUSTAR collaborators. Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European scleroderma trials and research. Chest 163, 586\u2013598 (2023).","journal-title":"Chest"},{"key":"1044_CR113","first-page":"154","volume":"5","author":"ER Volkmann","year":"2015","unstructured":"Volkmann, E. R. et al. Development of a composite outcome measure for systemic sclerosis related interstitial lung disease. Rheumatology 5, 154 (2015).","journal-title":"Rheumatology"},{"key":"1044_CR114","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/annrheumdis-2021-220702","volume":"81","author":"MO Becker","year":"2022","unstructured":"Becker, M. O. et al. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Ann. Rheum. Dis. 81, 507\u2013515 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR115","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1165\/rcmb.2021-0112OC","volume":"66","author":"LRK Penke","year":"2022","unstructured":"Penke, L. R. K., Speth, J., Wettlaufer, S., Draijer, C. & Peters-Golden, M. Bortezomib inhibits lung fibrosis and fibroblast activation without proteasome inhibition. Am. J. Respir. Cell Mol. Biol. 66, 23\u201337 (2022).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1044_CR116","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/thoraxjnl-2011-200717","volume":"67","author":"GM Mutlu","year":"2012","unstructured":"Mutlu, G. M. et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-\u03b21 signalling. Thorax 67, 139\u2013146 (2012).","journal-title":"Thorax"},{"key":"1044_CR117","doi-asserted-by":"publisher","first-page":"109723","DOI":"10.1016\/j.intimp.2023.109723","volume":"116","author":"N Bellamri","year":"2023","unstructured":"Bellamri, N. et al. Effects of ruxolitinib on fibrosis in preclinical models of systemic sclerosis. Int. Immunopharmacol. 116, 109723 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"1044_CR118","doi-asserted-by":"publisher","first-page":"220206","DOI":"10.1183\/16000617.0206-2022","volume":"32","author":"M Kolb","year":"2023","unstructured":"Kolb, M., Crestani, B. & Maher, T. M. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur. Respir. Rev. 32, 220206 (2023).","journal-title":"Eur. Respir. Rev."},{"key":"1044_CR119","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon, J. K. et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol. 70, 308\u2013316 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1044_CR120","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","volume":"75","author":"Z Brkic","year":"2016","unstructured":"Brkic, Z. et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann. Rheum. Dis. 75, 1567\u20131573 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR121","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98380","volume":"3","author":"S Kafaja","year":"2018","unstructured":"Kafaja, S. et al. pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI Insight 3, e98380 (2018).","journal-title":"JCI Insight"},{"key":"1044_CR122","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa1114576","volume":"370","author":"L van Bon","year":"2014","unstructured":"van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433\u2013443 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1044_CR123","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/annrheumdis-2020-218439","volume":"80","author":"RL Ross","year":"2021","unstructured":"Ross, R. L. et al. Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma. Ann. Rheum. Dis. 80, 920\u2013929 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1044_CR124","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nri.2017.21","volume":"17","author":"AP West","year":"2017","unstructured":"West, A. P. & Shadel, G. S. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat. Rev. Immunol. 17, 363\u2013375 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"1044_CR125","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40674-021-00188-9","volume":"7","author":"M Wu","year":"2021","unstructured":"Wu, M. & Assassi, S. Dysregulation of type 1 interferon signaling in systemic sclerosis: a promising therapeutic target? Curr. Treat. Opt. Rheumatol. 7, 349\u2013360 (2021).","journal-title":"Curr. Treat. Opt. Rheumatol."},{"key":"1044_CR126","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar4492","volume":"16","author":"A Goldberg","year":"2014","unstructured":"Goldberg, A. et al. Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res. Ther. 16, R57 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"1044_CR127","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1183\/09031936.00010910","volume":"38","author":"NS Goh","year":"2011","unstructured":"Goh, N. S. et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur. Respir. J. 38, 184\u2013190 (2011).","journal-title":"Eur. Respir. J."},{"key":"1044_CR128","doi-asserted-by":"publisher","first-page":"103323","DOI":"10.1016\/j.resp.2019.103323","volume":"273","author":"D Bennett","year":"2020","unstructured":"Bennett, D. et al. Elevated level of galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis. Respir. Physiol. Neurobiol. 273, 103323 (2020).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"1044_CR129","unstructured":"Galecto. Galecto Announces Topline Results from Phase 2b GALACTIC-1 trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis https:\/\/ir.galecto.com\/news-releases\/news-release-details\/galecto-announces-topline-results-phase-2b-galactic-1-trial (2023)."},{"key":"1044_CR130","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann, C. et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann. Rheum. Dis. 82, 1117\u20131120 (2023).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01044-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01044-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01044-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T09:04:37Z","timestamp":1703149477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01044-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01044-x","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"6 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare\u00a0no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}